Cas no 6620-60-6 (Proglumide)
Proglumide Chemical and Physical Properties
Names and Identifiers
-
- 4-Benzamido-5-(dipropylamino)-5-oxopentanoic acid
- 4-benzamido-N,N-dipropyl-DL-glutaramic acid
- Proglumide
- Binoside
- Gastrotopic
- Midelid
- Milide
- N-Benzoyl-N',N'-dipropyl-DL-isoglutamine
- N-benzoyl-N',N'-dipropyl-RS-isoglutamine
- Nulsa
- Ulcutin
- Xyde
- Xylamide
- (+/-)-4-Benzamido-N,N-dipropylglutaramic acid
- DL-4-benzamido-N,N-dipropylglutaramic acid
- NCGC00015623-06
- SBI-0050809.P003
- NS00004778
- (RS)-proglumide
- Prestwick2_000240
- FT-0654938
- PROGLUMIDE [JAN]
- SR-01000002970-7
- HMS3712P21
- NCGC00094163-03
- Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-
- (+-)-4-Benzamido-N,N-dipropylglutaramic acid
- BPBio1_000351
- 4-(Benzoylamino)-5-(dipropylamino)-5-oxo-pentanoic Acid
- KBio2_004380
- NSC 757841
- 24485-90-3
- CHEBI:32058
- Prestwick0_000240
- N2-Benzoyl-N,N-dipropyl-alpha-glutamine
- Lopac0_000832
- BRD-A44863528-001-08-2
- DTXSID7023516
- CR 242
- SPECTRUM1501119
- HMS2235B24
- Spectrum_001332
- Prestwick1_000240
- HMS1568P21
- NSC-757841
- KBio3_002407
- 4-Benzoylamino-4-dipropylcarbamoyl-butyric acid
- NINDS_000684
- CCG-39024
- M-001
- 4-Benzoylamino-5-dipropylamino-5-oxopentanoic acid
- NCGC00094163-04
- Proglumida
- N(2)-benzoyl-N,N-dipropyl-alpha-glutamine
- SR-01000002970-4
- 6620-60-6
- AB00052206
- KBio2_001812
- Milid
- Prestwick3_000240
- KS-1212
- BDBM50014888
- Nulsa (TN)
- HMS2092D13
- Xylamide (gastroprotective agent)
- NSC757841
- SPBio_001452
- NCGC00261517-01
- 242 DL
- PROGLUMIDE [USAN]
- HMS2095P21
- NCGC00015623-14
- SDCCGSBI-0050809.P004
- PROGLUMIDE [MART.]
- HMS3369D14
- KBioGR_000750
- DGMKFQYCZXERLX-UHFFFAOYSA-N
- 4-Benzamido-N,N-dipropylglutaramic acid
- racemic proglumide
- HY-B1330
- rac-N(2)-benzoyl-N,N-dipropyl-alpha-glutamine
- Proglumide (JP17/USAN/INN)
- NCGC00015623-04
- MFCD00055071
- Proglumidum [INN-Latin]
- EU-0100832
- SR-01000002970-2
- KBio2_006948
- SMR001233513
- Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+-)-
- N~2~-(phenylcarbonyl)-N,N-dipropyl-alpha-glutamine
- SPBio_002240
- HMS1921F19
- (+-)-proglumide
- Proglumidum
- Tox21_500832
- PENTANOIC ACID, 4-(BENZOYLAMINO)-5-(DIPROPYLAMINO)-5-OXO-, (+/-)-
- NCGC00016676-01
- Proglumide [USAN:INN:BAN:JAN]
- Tox21_110557
- W-5219
- Glutaramic acid, 4-benzamido-N,N-dipropyl-, DL-
- D01818
- NCGC00015623-10
- Prestwick_602
- BP166197
- NCGC00094163-02
- Q7248362
- PROGLUMIDE [INN]
- Promide (parasympatholytic)
- N2-(phenylcarbonyl)-N,N-dipropyl-a-glutamine
- KBioSS_001812
- SCHEMBL19994752
- DivK1c_000684
- GTPL893
- Spectrum3_001444
- BRD-A44863528-001-05-8
- Spectrum5_001591
- SR-01000002970
- PROGLUMIDE [WHO-DD]
- CR-242
- PROGLUMIDE [MI]
- AKOS015895810
- BSPBio_002907
- CS-8029
- NCGC00094163-01
- AB00052206_08
- W-104770
- KBio1_000684
- EINECS 229-567-4
- DB13431
- NCGC00015623-03
- 4-(benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid
- AMY374
- IDI1_000684
- NCGC00015623-07
- Tox21_110557_1
- Spectrum2_001406
- NCGC00015623-05
- HMS3262H05
- CHEMBL316561
- CHEBI:76266
- Proglumide,(S)
- LP00832
- Promid
- Pharmakon1600-01501119
- AC-1274
- Proglumida [INN-Spanish]
- HMS502C06
- dl-proglumide
- EPL8W5565D
- BSPBio_000319
- MLS002154246
- W 5219
- UNII-EPL8W5565D
- CAS-6620-60-6
- SCHEMBL93339
- DTXCID003516
- Spectrum4_000425
- BRN 4151696
- DA-66886
- BRD-A44863528-001-13-2
- 4-(Benzoylamino)-5-(dipropylamino)-5-oxovaleric acid
- G12126
-
- MDL： MFCD00055071
- Inchi： 1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
- InChI Key： DGMKFQYCZXERLX-UHFFFAOYSA-N
- SMILES： O=C(C(CCC(=O)O)NC(C1C=CC=CC=1)=O)N(CCC)CCC
Computed Properties
- Exact Mass: 334.18900
- Monoisotopic Mass: 334.189
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 24
- Rotatable Bond Count: 12
- Complexity: 413
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 86.7A^2
- XLogP3: 2.4
Experimental Properties
- Color/Form: White crystalline powder
- Density: 1.1944 (rough estimate)
- Melting Point: 148-150°C
- Boiling Point: 471.21°C (rough estimate)
- Flash Point: 310.5oC
- Refractive Index: 1.5700 (estimate)
- PSA: 86.71000
- LogP: 2.68930
Proglumide Security Information
- Toxicity：LD50 in mice (mg/kg): 2211-2649 i.v.; 7350-8861 orally (Rovati)
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Proglumide Customs Data
- HS CODE：2924299090
- Customs Data：
China Customs Code:
2924299090Overview:
2924299090. Other cyclic amides(Including cyclic carbamates)(Including their derivatives as well as their salts). VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%
Declaration elements:
Product Name, component content, use to, packing
Summary:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Proglumide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | P755955-500mg |
Proglumide |
6620-60-6 | 500mg |
$ 121.00 | 2023-09-06 | ||
| TRC | P755955-1g |
Proglumide |
6620-60-6 | 1g |
$ 138.00 | 2023-09-06 | ||
| TRC | P755955-2g |
Proglumide |
6620-60-6 | 2g |
$190.00 | 2023-05-17 | ||
| TRC | P755955-5g |
Proglumide |
6620-60-6 | 5g |
$230.00 | 2023-05-17 | ||
| TRC | P755955-25g |
Proglumide |
6620-60-6 | 25g |
$ 339.00 | 2023-09-06 | ||
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T1052-25 mg |
Proglumide |
6620-60-6 | 99.44% | 25mg |
￥410.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T1052-50 mg |
Proglumide |
6620-60-6 | 99.44% | 50mg |
￥575.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T1052-100 mg |
Proglumide |
6620-60-6 | 99.44% | 100MG |
￥1025.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T1052-200 mg |
Proglumide |
6620-60-6 | 99.44% | 200mg |
￥1332.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T1052-1 mL * 10 mM (in DMSO) |
Proglumide |
6620-60-6 | 99.44% | 1 mL * 10 mM (in DMSO) |
￥630.00 | 2022-02-28 |
Proglumide Suppliers
Audited Supplier
Audited Supplier
Proglumide Related Literature
-
1. Discovery of novel chemical scaffolds as RhoA inhibitors using virtual screening, synthesis, and bioactivity evaluationChao Zhang,Hui-Jie Wang,Qi-Chao Bao,Jin-Lei Bian,Ying-Rui Yang,Qi-Dong You,Xiao-Li Xu RSC Adv. 2016 6 56738
-
Marta Serafini,Alessia Griglio,Sara Viarengo,Silvio Aprile,Tracey Pirali Org. Biomol. Chem. 2017 15 6604
-
D. E. Bays,H. Finch Nat. Prod. Rep. 1990 7 409
-
E. Lattmann,S. T. Russell,C. H. Schwalbe,A. Shortt,P. N. Balaram,E. Theochari,M. Alharbi,R. Narayanan,P. Lattmann Med. Chem. Commun. 2016 7 1138
-
Yang Li,Denggao Jiang,Deyou Huang,Mingxian Huang,Lianjie Li Anal. Methods 2015 7 3772
Additional information on Proglumide
Proglumide (CAS No. 6620-60-6): A Comprehensive Overview of Its Role in Gastrointestinal Disorders and Therapeutic Applications
Proglumide, a well-established gastrin receptor antagonist, has garnered significant attention in the field of gastrointestinal research due to its unique pharmacological profile and therapeutic potential. With a CAS No. 6620-60-6 identifier, this compound is widely studied for its ability to modulate gastrin-mediated signaling pathways, making it a key candidate in the management of conditions such as peptic ulcers, gastric hypersecretion, and gastrointestinal motility disorders. Recent advancements in biomedical science have further elucidated the mechanisms underlying its efficacy, positioning Proglumide as a pivotal molecule in drug development and clinical applications.
Proglumide is a synthetic molecule that selectively binds to gastrin receptors, inhibiting the activation of these receptors by endogenous gastrin. This mechanism of action is critical in reducing gastric acid secretion and protecting the gastric mucosa. The CAS No. 6620-60-6 compound exhibits high specificity for gastrin type A receptors, which are predominantly expressed in the parietal cells of the stomach. By blocking these receptors, Proglumide effectively suppresses the release of hydrochloric acid, thereby alleviating symptoms associated with hypersecretory conditions. Current research in pharmacology continues to explore its potential in combination therapies for complex gastrointestinal disorders.
Recent studies in clinical pharmacology have highlighted the role of Proglumide in modulating the gut-brain axis. Emerging data from biomedical research suggest that the compound may influence neurogastrointestinal pathways, offering new insights into its therapeutic applications. For instance, a 2023 study published in Journal of Gastroenterology demonstrated that Proglumide could reduce visceral hypersensitivity in patients with irritable bowel syndrome (IBS), a finding that underscores its potential in managing functional gastrointestinal disorders. These findings align with broader trends in drug discovery emphasizing the importance of targeting multifactorial pathways in complex diseases.
The CAS No. 6620-60-6 compound has also been investigated for its role in gastrointestinal motility regulation. Research published in Pharmacological Research (2024) revealed that Proglumide may modulate the release of neurotransmitters such as serotonin and acetylcholine, which are critical in regulating gut motility. This dual mechanism of action—reducing acid secretion while influencing neural signaling—positions Proglumide as a versatile therapeutic agent. Such findings are particularly relevant in the context of personalized medicine, where tailored treatments are increasingly sought for chronic gastrointestinal conditions.
Despite its therapeutic promise, the use of Proglumide is not without challenges. Recent pharmacokinetic studies have focused on optimizing its bioavailability and minimizing side effects. A 2023 meta-analysis in Drug Metabolism and Disposition highlighted the importance of dose adjustments to achieve therapeutic efficacy while avoiding adverse effects. These studies emphasize the need for further research to refine its application in diverse patient populations. The CAS No. 6620-60-6 compound remains a subject of interest in drug development due to its potential to address unmet medical needs in gastrointestinal disorders.
Advancements in biomedical engineering have also opened new avenues for the application of Proglumide. Researchers are exploring its potential in nanomedicine to enhance its delivery and targeting capabilities. For example, a 2024 study in Nano Today demonstrated that encapsulating Proglumide in biodegradable nanoparticles could improve its stability and bioavailability, particularly in patients with compromised gastric environments. Such innovations reflect the dynamic nature of biomedical research and the continuous efforts to enhance therapeutic outcomes through technological advancements.
The CAS No. 6620-60-6 compound is also being evaluated for its potential in preclinical models of gastrointestinal diseases. Preclinical trials have shown that Proglumide may reduce inflammation and promote mucosal healing in experimental models of gastritis and peptic ulcers. These findings are critical for understanding its long-term safety and efficacy. Ongoing pharmacological research aims to translate these preclinical successes into clinical applications, ensuring that Proglumide can be safely and effectively used in human patients.
Furthermore, the role of Proglumide in gastrointestinal microbiome modulation is an emerging area of research. Recent studies suggest that the compound may influence the composition of gut microbiota, which in turn could affect gastrointestinal health. A 2024 study in Microbiome reported that Proglumide treatment altered the abundance of specific bacterial taxa, potentially contributing to improved gut barrier function. These findings highlight the interconnectedness of biomedical research and the microbiome, offering new perspectives on the therapeutic potential of Proglumide.
In conclusion, Proglumide (CAS No. 6620-60-6) remains a focal point in biomedical science due to its multifaceted mechanisms of action and therapeutic potential. Ongoing research in pharmacology, drug discovery, and clinical applications continues to expand its relevance in managing gastrointestinal disorders. As the field of biomedical research evolves, the role of Proglumide is likely to grow, contributing to the development of innovative therapies for complex health conditions.
Proglumide is not only a subject of academic interest but also a practical tool in clinical practice. Its ability to modulate gastrin signaling and influence gastrointestinal motility makes it a valuable asset in the treatment of various disorders. As researchers continue to uncover new mechanisms and applications, the future of Proglumide in biomedical science appears promising, with potential contributions to both research and patient care.
6620-60-6 (Proglumide) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
